News >

FDA Approves Olaparib for BRCA+ Breast Cancer

Jason M. Broderick @jasoncology
Published: Friday, Jan 12, 2018

Richard Pazdur, MD

Richard Pazdur, MD
The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Additionally, HR-positive patients should have prior endocrine therapy or not be considered appropriate for such treatment.

Olaparib was well-tolerated overall, with less than 2.0% of patients discontinuing treatment due to toxicity, compared with 2.2% in the chemotherapy arm. The main adverse events (AEs) associated with the PARP inhibitor were nausea, anemia, and fatigue.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication